



NDA 209401/S-002

SUPPLEMENT APPROVAL

Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals company)
Attention: Fojan Zamanian
Senior Director Regulatory Affairs
3170 Porter Drive
Palo Alto, CA 94304

Dear Ms. Zamanian:

Please refer to your Supplemental New Drug Application (sNDA) dated and received June 14, 2019, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vyxeos (daunorubicin and cytarabine) liposome for injection.

This “Changes Being Effected in 30 days” supplemental new drug application provides for changes to the in-line filter use in section 2.4 Administration Instructions of the USPI.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format,

that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Adijat Abass-Fasuyi, Regulatory Business Process Manager, at (301) 796 - 3609.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Chief, Branch I
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure:

Content of Labeling



Ramesh
Raghavachari

Digitally signed by Ramesh Raghavachari
Date: 1/13/2020 03:30:04PM
GUID: 502d0913000029f375128b0de8c50020